NAMSA and Advanced Medical Solutions Announce Preferred Partnership

(AIM:AMS) Advanced Medical Solutions Group plc (AMS) and NAMSA have entered into a preferred partnership to accelerate the development and commercialization of AMS's tissue-healing product portfolio. Under the agreement, AMS gains consolidated access to NAMSA's full suite of services, including regulatory, quality and biological safety consulting, biocompatibility, chemical characterization, microbiology, package integrity testing, and clinical research from study design through post-market evidence generation. The partnership is designed to reduce handoffs between providers, improve continuity across development programs, and shorten the path from design to market for AMS's surgical and advanced wound care portfolio. NAMSA will provide its regulatory, biological safety, testing, and clinical research services to support AMS's accelerated development and global market access. AMS's product brands include LIQUIBAND®, RESORBA®, ActivHeal®, VITA™Clip, IFABOND®, LIQUIBANDFIX8®, LIQUIFIX™, and Seal-G®. The AMS portfolio covers tissue adhesives, sutures, haemostats, internal fixation devices, sealants, and advanced wound care dressings. AMS products are sold in more than 100 countries. AMS was founded in 1991 and is headquartered in Winsford, UK. AMS operates through 24 international sites. AMS employs more than 1,800 people worldwide. NAMSA is described as a world-leading MedTech Contract Research Organization (CRO) offering end-to-end development services. The partnership aims to help AMS clear regulatory hurdles and bring technologies to patients faster by integrating NAMSA's preclinical and clinical expertise with AMS's surgical and advanced wound care pipeline. The announcement highlights that MedTech manufacturers face evolving regulatory requirements and rising demands for clinical and biological safety evidence, which can extend development timelines and increase costs. NAMSA's integrated model is intended to help sponsors manage risk earlier and move products forward more efficiently. Brian Smith, CEO of NAMSA, commented that the agreement reflects a strong foundation of trust and collaboration and marks an exciting new chapter in the relationship between the two companies.

No Intention to Make an Offer for AMS

TA Associates Management, L.P. has announced that it does not intend to make an offer for Advanced Medical Solutions Group plc ("AMS"). This follows a previous announcement on 18 April 2026 that funds affiliated with TA Associates (UK), LLP were considering a possible offer for the entire issued and to be issued share capital of AMS. The announcement falls under Rule 2.8 of the City Code on Takeovers and Mergers. TA and any persons acting in concert with it will be bound by the restrictions set out in Rule 2.8 of the Code, except under certain specified circumstances. The information is provided by RNS, the news service of the London Stock Exchange, in the United Kingdom.

Form 8 - Advanced Medical Solutions Group plc

Advanced Medical Solutions Group plc has released a Form 8 announcement, which typically relates to dealings in relevant securities of the company. The announcement is dated 20 April 2026 and was disseminated via RNS. This filing is important for investors as it may indicate insider transactions or significant shareholding changes, which can impact market perception and regulatory compliance. However, the announcement does not provide details on financial performance or operational updates.